European private equity firm Cinven has acquired the Amdipharm Group, a family-owned niche pharmaceuticals business, for a total consideration of £367 M (US$589 M). Amdipharm will initially operate independently but Cinven intends to merge it with Mercury Pharma, which it bought in September 2012 from rival HgCapital. The acquisition of Amdipharm will double the size of this speciality pharmaceutical business in terms of revenue and profit and significantly expand its geographic footprint. Amdipharm’s founders will retain a significant minority stake in the combined business.